Premium
Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium
Author(s) -
Botte L.,
Gilles C.,
Evrard J. L.,
Mesters P.,
Wolfram C.,
Berger M.,
Hellstern K.,
Ward J.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05323.x
Subject(s) - moclobemide , placebo , antidepressant , medicine , rating scale , hamilton rating scale for depression , depression (economics) , psychology , major depressive disorder , developmental psychology , alternative medicine , macroeconomics , pathology , hippocampus , economics , amygdala
Moclobemide was compared with placebo for antidepressant activity, tolerance and safety in 2 parallel groups of 23 and 24 depressed patients. At the end of treatment (4 weeks or longer), 9 patients on moclobemide (41%) showed an improvement >50% on the Hamilton Rating Scale for Depression, compared with only 4 (17%) of those on placebo. The overall assessment of efficacy was significantly better for moclobemide (good or very good results in 50% of patients) than for placebo (80% poor results). Moclobemide was well or very well tolerated by 85% of patients and placebo by 100%. Moclobemide was thus shown to be clearly more effective than placebo and only slightly less well tolerated.